Skip to main content
TCMD
NASDAQ Industrial Applications And Services

Tactile Medical 10-Q: Q3 Revenue $91.9M, New COO Named, $75.1M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$22.87
Mkt Cap
$518.058M
52W Low
$14.84
52W High
$37.77
52W Position info
54% above low
Off High info
39% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TCMD sits 54% above its 52-week low of $14.84.

Summary

Tactile's Q3 10-Q confirms $91.9M revenue (+7%) and $0.31 diluted EPS, adds a new COO and an executive departure, and shows cash down to $75.1M after $12.5M of buybacks.


Key Events · Earnings and Guidance · TCMD

  • Q3 Revenue Grows 7% to $91.9M

    Lymphedema sales and rentals rose 13% to $81.8M, offsetting a 25% decline in airway clearance to $10.0M tied to the AffloVest DME inventory transition.

  • Margins Expand, Net Income Slips

    Gross margin rose to 77% from 76%, but operating expenses grew 13% to $60.9M and net income fell to $7.2M ($0.31 diluted) from $8.2M ($0.36).

  • New COO Appointed

    Stephen A. Kiewiet became Chief Operating Officer on November 2, 2026, with a $385,000 base salary, $350,000 sign-on equity split between RSUs and PSUs, and a 45% target bonus.

  • SVP Business Development Role Eliminated

    Kristie Burns was notified October 27, 2026 that her position ends November 2, 2026; she stays as an employee through December 31, 2026 with severance and a waived 2026 MIP employment condition.


Analysis · TCMD · Industrial Applications And Services

The 10-Q confirms the Q3 numbers already released this morning — revenue up 7% to $91.9M, net income down to $7.2M ($0.31 diluted) from $8.2M — but adds two items the 8-K did not carry: a new Chief Operating Officer (Stephen Kiewiet, $385,000 salary plus $350,000 sign-on equity) and the elimination of the SVP Business Development role. The balance sheet is the real story: cash fell to $75.1M from $83.4M at year-end after $12.5M of buybacks at a $24.92 average, and $2.2M of LymphaTech earnout becomes payable by November 12. The False Claims Act suits are now settled and dismissed, leaving only a $0.2M fee dispute.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TCMD was trading at $22.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $14.84 to $37.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TCMD - Latest Insights

TCMD
Nov 02, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $22.87
Real-time Price: $26.10 info
Change: +$3.23 (+14%) info
Market Cap: $591.844M info
TCMD
Nov 02, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.87
Real-time Price: $26.10 info
Change: +$3.23 (+14%) info
Market Cap: $591.844M info
TCMD
Aug 10, 2026, 4:21 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $29.72
Real-time Price: $26.10 info
Change: -$3.62 (-12%) info
Market Cap: $591.844M info
TCMD
Jul 13, 2026, 9:23 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.83
Real-time Price: $26.10 info
Change: -$3.73 (-13%) info
Market Cap: $591.844M info
TCMD
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $29.83
Real-time Price: $26.10 info
Change: -$3.73 (-13%) info
Market Cap: $591.844M info